

Geoffrey C Buckle

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1302873/geoffrey-c-buckle-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

30,329
citations

15
h-index

28
g-index

28
ext. papers

35,610
ext. citations

15.9
avg, IF

7.51
L-index

#	Paper	IF	Citations
23	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012 , 380, 2197-223	4.0	5768
22	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012 , 380, 2163-96	4.0	4971
21	Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015 , 385, 117-71	4.0	4599
20	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015 , 386, 743-800	4.0	3802
19	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1545-1602	4.0	3801
18	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1459-1544	4.0	3525
17	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1603-1658	4.0	1216
16	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015 , 386, 2145-91	4.0	1203
15	The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e2865	4.8	583
14	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1725-1774	4.0	413
13	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 507-12	2.2	151
12	The global burden of disease study 2013: What does it mean for the NTDs?. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005424	4.8	135
11	Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. <i>BJU International</i> , 2012 , 110, 1729-35	5.6	64
10	Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. <i>International Journal of Cancer</i> , 2016 , 139, 1231-40	7.5	30
9	Factors influencing time to diagnosis and initiation of treatment of endemic Burkitt Lymphoma among children in Uganda and western Kenya: a cross-sectional survey. <i>Infectious Agents and Cancer</i> , 2013 , 8, 36	3.5	28
8	Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. <i>Urology</i> , 2013 , 81, 611-6	1.6	9
7	A Case-Control Study to Evaluate Environmental and Lifestyle Risk Factors for Esophageal Cancer in Tanzania. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 305-316	4	9

6	Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2014 , 91	2.6	7
5	Assessment of liver disease (noninvasive methods). <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 465-71	4.2	7
4	Improving Access to Self-Expanding Metal Stents for Patients With Esophageal Cancer in Eastern Africa: A Stepwise Implementation Strategy. <i>JCO Global Oncology</i> , 2021 , 7, 118-126	3.7	3
3	Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies. <i>International Journal of Cancer</i> , 2021 , 148, 1115-1131	7.5	2
2	Risk Factors Associated With Early-Onset Esophageal Cancer in Tanzania.. <i>JCO Global Oncology</i> , 2022 , 8, e2100256	3.7	1
1	Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study.. <i>BMC Cancer</i> , 2022 , 22, 82	4.8	